AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
PDF (3.2 MB)
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Rapid Communication | Open Access

Juvenile idiopathic arthritis-associated RIG-I S144F variant inhibits type Ⅰ interferon signaling by blocking TRIM25-media ted ubiquitination

Li Zhanga,dSong Zhanga,c,dYaoyao Shangguanb,dWanming HuangaHaolan JinaLili LiaYuyin QiaYuxia ZhangaPing Zenga,c( )Huifang Xiana( )
Guangzhou Institute of Pediatrics, Guangzhou Women and Children’s Medical Center, Guangzhou Medical University, Guangzhou, Guangdong 510623, China
The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, Guangdong 325000, China
Department of Allergy, Immunology and Rheumatology, Guangzhou Women and Children’s Medical Center, Guangzhou Medical University, Guangzhou, Guangdong 510623, China

Peer review under the responsibility of Chongqing Medical University.

d These authors contributed equally to this paper.

Show Author Information

References

【1】
【1】
 
 
Genes & Diseases

{{item.num}}

Comments on this article

Go to comment

< Back to all reports

Review Status: {{reviewData.commendedNum}} Commended , {{reviewData.revisionRequiredNum}} Revision Required , {{reviewData.notCommendedNum}} Not Commended Under Peer Review

Review Comment

Close
Close
Cite this article:
Zhang L, Zhang S, Shangguan Y, et al. Juvenile idiopathic arthritis-associated RIG-I S144F variant inhibits type Ⅰ interferon signaling by blocking TRIM25-media ted ubiquitination. Genes & Diseases, 2026, 13(4). https://doi.org/10.1016/j.gendis.2025.101791

5

Views

0

Downloads

0

Crossref

0

Web of Science

0

Scopus

0

CSCD

Received: 01 April 2025
Published: 07 August 2025
© 2025 The Authors.

This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).